Cellsource Co Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan. The company provides processing services to extract adipose-derived stem cells from patients’ adipose tissues, and to prepare platelet-rich plasma from patients’ blood; and offers support services for medical facilities providing regenerative medicine therapy, as well as manufacturing processed cells. It is also involved in the development and sale of Signalift series of anti-aging products, including a serum. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.
Metrics to compare | 4880 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4880PeersSector | |
---|---|---|---|---|
P/E Ratio | - | −2.5x | −0.5x | |
PEG Ratio | - | 0.03 | 0.00 | |
Price/Book | 2.3x | 1.2x | 2.6x | |
Price / LTM Sales | - | 1.3x | 3.3x | |
Upside (Analyst Target) | 28.8% | 98.8% | 43.5% | |
Fair Value Upside | Unlock | 23.1% | 6.9% | Unlock |